Statement 9: For patients with clinically detectable stage III melanoma harboring a BRAF V600 mutation, neoadjuvant systemic therapy with BRAF-targeted therapy for a duration of 8-12 weeks may be considered as an alternative to immunotherapy. The gene discussed is BRAF; the disease is melanoma.